# KLRA (Kailera Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Kailera Therapeutics, Inc. reported $1.08B in total assets through September 30, 2026 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/KLRA
- Markdown: https://convexityos.com/fundamentals/KLRA.md
- SEC CIK: 0002096997
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:24 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002096997&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2026 | -- | Sep 30, 2026 |
| Operating Income | FY 2026 | -- | Operating profit |
| Net Income | FY 2026 | -- | GAAP bottom line |
| Diluted EPS | FY 2026 | -- | Split-adjusted |
| Free Cash Flow | FY 2026 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $901.5M | Total debt: $9.97M |

## Income Statement

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $84.67M | $101.1M | $70.87M | $26.99M | $19.52M | $10.13M |
| Total Operating Expenses | $106.3M | $121.4M | $84.66M | $40.11M | $30.65M | $20.46M |
| **Operating Income** | -$106.3M | -$121.4M | -$84.66M | -$40.11M | -$30.65M | -$20.46M |
| **EBITDA** | -$106.2M | -$121.3M | -$84.56M | -$40.05M | -$30.59M | -$20.39M |
| **Net Income** | -$95.67M | -$111.3M | -$78.86M | -$39.62M | -$28.95M | -$17.98M |
| Basic EPS | -$0.74 | -$1.09 | -$3,650.00 | -$39,623.00 | -$28,947.00 | -$17,983.00 |
| **Diluted EPS** | -$0.74 | -$1.09 | -$3,650.00 | -$39,623.00 | -$28,947.00 | -$17,983.00 |
| Basic Shares Outstanding | 129.7M | 102.2M | 21.6K | 1 | 1 | 1 |
| Diluted Shares Outstanding | 129.7M | 102.2M | 21.6K | 1 | 1 | 1 |

## Balance Sheet

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
| --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $106.5M | $130.3M | $111.8M | $160.3M |
| Short-Term Investments | $794.9M | $786.4M | $407.3M | $385.8M |
| **Cash & Short-Term Investments** | $1.04B | $1.17B | $581.9M | $546.1M |
| Other Current Assets | $4.89M | $395K | $360K | $4.22M |
| **Total Current Assets** | $919.8M | $929.2M | $530.3M | $557.5M |
| Property, Plant & Equipment, Net | $1.65M | $1.75M | $1.85M | $1.96M |
| Long-Term Investments | $136.2M | $255.1M | $62.75M | $106.7M |
| Other Non-Current Assets | $63K | $90K | $5.59M | $2.72M |
| **Total Non-Current Assets** | $162.4M | $282.2M | $94.44M | $134.8M |
| **Total Assets** | $1.08B | $1.21B | $624.8M | $692.3M |
| Accounts Payable | $9.43M | $19.20M | $7.09M | $7.53M |
| **Total Current Liabilities** | $42.12M | $83.65M | $54.84M | $46.41M |
| Other Non-Current Liabilities | $67K | $135K | $201K | $270K |
| **Total Non-Current Liabilities** | $8.95M | $9.30M | $9.64M | $9.98M |
| **Total Liabilities** | $51.06M | $92.95M | $64.48M | $56.39M |
| **Total Debt (incl. Leases)** | $9.97M | $10.22M | $10.47M | $10.75M |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$654.5M | -$558.8M | -$447.5M | -$368.7M |
| Accumulated Other Comp. Income | -$3.74M | -$1.79M | -$532K | $229K |
| **Total Stockholders' Equity** | $1.03B | $1.12B | -$432.1M | -$356.5M |
| Total Equity | $1.03B | $1.12B | -$432.1M | -$356.5M |

## Cash Flow Statement

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$95.67M | -$111.3M | -$78.86M | -$39.62M | -$28.95M | -$17.98M |
| Depreciation & Amortization | $101K | $101K | $101K | $63K | $62K | $63K |
| Stock-Based Compensation | $9.92M | $8.34M | $3.94M | $4.27M | $1.63M | $1.52M |
| Change in Payables | -$9.77M | $12.34M | -$495K | $154K | -$837K | $645K |
| **Operating Cash Flow** | -$133.7M | -$77.53M | -$68.31M | -$29.70M | -$26.23M | -$18.20M |
| Purchases of Investments | -$37.06M | -$689.8M | -$48.45M | -$42.28M | -$82.17M | -$54.44M |
| **Investing Cash Flow** | $110.8M | -$571.0M | $22.85M | $26.48M | -$74.17M | -$54.44M |
| **Financing Cash Flow** | -$922K | $667.0M | -$2.98M | -$243K | $100.0M | $0 |
| **Net Change in Cash** | -$23.76M | $18.48M | -$48.44M | -$3.46M | -$403K | -$72.64M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Current Ratio | 21.84x | 11.11x | 9.67x | -- | -- | -- |
| Quick Ratio | 24.64x | 14.01x | 10.61x | -- | -- | -- |
| Debt to Equity | 0.01x | 0.01x | -- | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
